 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
||
| ON THIS PAGE | Company News About GeneThera Investor FAQ's Our Board of Directors |
|||
|
||||
| COMPANY NEWS | GeneThera Enters Into Agreement With IZSLER—Jun 18, 2007 GeneThera Enters Into Letter of Intent With Mezey Howarth Racing Stables—Jun 18, 2007 GeneThera Has Entered Into Negotiations to Provide Testing for Mezey Howarth Racing Stables—Jun 13, 2007 GeneThera Receives NIH Contract—Jun 12, 2007 GeneThera's Update on Operations in Italy—Jun 07, 2007 GeneThera's Update on Operations in Mexico—Jun 07, 2007 GeneThera's Annual Stockholders' Meeting—Jun 06, 2007 GeneThera's New Governance and Annual Stockholder's Meeting—Jun 06, 2007 GeneThera, Inc.'s Transfer Agent Requesting Beneficial Shareholders List From Brokerage Firms—May 31, 2007 GeneThera, Inc.'s Transfer Agent Requesting Beneficial Shareholders List From Brokerage Firms—May 31, 2007 GeneThera's Ex-Dividend Date—May 17, 2007 GeneThera to Institute Strategic Plan—May 09, 2007 GeneThera Explores Potential Acquisition of Other Companies—May 09, 2007 GeneThera Announces 10th Case of Mad Cow in Canada—May 08, 2007 GeneThera's Cash Dividend—May 08, 2007 GeneThera to Expand Mad Cow Testing to Foreign Markets—May 07, 2007 Congressional Hearing: Is Our Food Safe?—Apr 26, 2007 GeneThera Announces a Cash Dividend—Apr 18, 2007 GeneThera in Preliminary Talks for Mad Cow Testing—Apr 16, 2007 GeneThera Files RW—Apr 13, 2007 GeneThera's Mad Cow Testing—Apr 12, 2007 GeneThera Announces Another Case of Mad Cow—Apr 11, 2007 GeneThera Developing Marketing Plan for Mad Cow Testing—Apr 11, 2007 Mad Cow: Is America Next?—Apr 10, 2007 What Is Mad Cow Disease—Apr 10, 2007 GeneThera, Inc. Announces That It Has Engaged The Mezey Howarth Group—Apr 09, 2007 Court Allows Private Testing for Mad Cow Disease—Apr 02, 2007 MN1 Research Issues GTHA, Inc. Buy Recommendation—Sep 21, 2006 Update: GeneThera, Inc., Willingham to Unveil Analysts Report on MN1.com—Sep 21, 2006 GeneThera Obtains Cooperation From The U.S.D.A. For Validation Of Live Blood Test For Mad Cow Disease—Jan 14, 2004 GeneThera, Inc.: Commercial Introduction of Live Blood Test for Mad Cow Disease—Jan 06, 2004 GeneThera, Inc. Announces Live Blood Test Now Available for Mad Cow Disease—Dec 30, 2003 GeneThera Signs Letter of Intent for Joint Venture With Oncology Sciences Corp. for Development of a Blood Diagnostic Test for Breast and Prostate Cancer—Dec 02, 2003 GeneThera Utilizes PURIVAX Technology to Develop Vaccine for Chronic Wasting Disease—Oct 14, 2003 |
|||
|
||||
| ABOUT GENETHERA | GeneThera is an international biotechnology company, dedicated since 1995 to improving food safety by applying the latest molecular technologies to eradicate farm animal disease. The company focuses on developing molecular diagnostic testing and vaccines in the belief that better technology use leads to a better life for all of mankind.
In the U.S., testing has previously only been done on suspected mad cow infected animals who must be killed in order for the testing to be completed. GeneThera’s testing system is designed to analyze a host of individual diseases. The company’s current priorities are Mad Cow Disease; Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, affecting cattle worldwide. |
|||
|
||||
| INVESTOR FAQ'S | Q. Where is GeneThera, Inc.’s common stock traded? A. GeneThera, Inc. is a fully reporting company trading on the electronic NASDAQ Over The Counter Bulletin Board, under the ticker symbol “GTHA”. Q. Under what industry is GeneThera, Inc.’s categorized? Q. What year was GeneThera, Inc. incorporated? Q. When was GeneThera, Inc.’s reversed merger? Q. Who is GeneThera, Inc.’s transfer agent? Q. What is the company’s CUSIP number? Q. Does GeneThera, Inc. pay a common stock dividend? Q. When does GeneThera, Inc. release earnings? Q. When is GeneThera, Inc.’s Annual Shareholders’ Meeting? Q. Who are GeneThera, Inc.’s independent accountants? Q. When is GeneThera, Inc.’s fiscal year end? Q. Where is GeneThera, Inc.’s headquarters? |
|||
|
||||
| OUR BOARD OF DIRECTORS | Dr. Tony Milici—Chairman of the Board, President & CEO Dr. Milici is a Ph.D. in Experimental Hematology and M.D. in Medicine and Surgery, receiving degrees from University of Rome (Italy) and Stanford University. His specialties include: molecular biology/biotechnology, Gene Therapy/Molecularly Oncology and Molecular. He has had extensive post-graduate training that includes a fellowship in the Department of Clinical Immunology with the University of Texas M.D. Anderson Cancer Center and Visiting Fellow at University of Rome's Laboratory of Cellular Immunology and Biochemistry. Among his post-graduate activities, Dr. Milici was an Assistant Professor at the Medical College of Georgia's Department of Pharmacology & Toxology as well as an Assistant Biochemist in the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center in Houston, TX. Prior to founding GeneThera, Inc., Dr. Milici was President & CEO of Genetrans, Inc. based in Augusta, GA., a diagnostics laboratory. For Dr. Milici, GeneThera is a realization of an ambition to demonstrate the commercial potential of molecular biotechnology. Dr. Thomas J. Slaga—Board Member Dr. Slaga is a Ph.D. in Physiology and Biophysics with undergraduate degrees in Biology/Chemistry. Since 1999, Dr. Slaga has served as an Adjunct Professor in the Department of Biochemistry & Molecular Biology at University of Colorado's Health Sciences Center located in Denver, CO. Dr. Slaga's career is steeped in research and development roles and affiliations concentrating on cancer. Examples include: Chair/Scientific Director for Cancer Causation and Prevention, the AMC Cancer Research Center located in Denver, CO; Director, Professor of Biochemistry at the University of Texas M.D. Anderson Cancer Center (Science Park-Research Division) located in Smithville, TX; and Group Leader and Research Staff Member, Skin Carcinogenesis and Tumor Promotion, Biology Division of the Oak Ridge National Laboratory in Oak Ridge, TN. Dr. Slaga's blend of scientific and management experience lends to GeneThera's board an important dimension vis-à-vis its development opportunities. Steven M. Grubner—Board Member Steven M. Grubner joined GeneThera, Inc.'s Board of Directors in May 2004, and served as our Chief Financial Officer from June of that year. Mr. Grubner resigned from that position in May 2006, being unable to relocate to Colorado from Illinois, but continued his board membership with GeneThera. Mr. Grubner has over twenty years of experience in the technology industry. He served as the president, administration and chief financial officer at HH Communications, Inc. from 1986 through to the completion of its merger with Datatec Systems, Inc. (DATC) in mid-1996. Until late 1999, he served as Datatec's vice president and General Counsel, a position that put him in charge of Datatec's public SEC filings, vendor contract negotiations, and internal employee agreements. |
|||
GeneThera Research | For The Breeder/Rancher | For The Public | Contact Us | Site Map | Privacy Policy